Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial

Introduction: This paper aims to evaluate the toxicity profile of additive gemcitabine to adjuvant taxane-based chemotherapy in breast cancer patients. Methods: Patients enrolled in this open-label randomized controlled Phase III study were treated with 3 cycles of epirubicin-fluorouracil-cyclophosp...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Geburtshilfe Frauenheilkd
Glavni autori: Schröder, L., Rack, B., Sommer, H., Koch, J. G., Weissenbacher, T., Janni, W., Schneeweiss, A., Rezai, M., Lorenz, R., Jäger, B., Schramm, A., Häberle, L., Fasching, P. A., Friedl, T. W. P., Beckmann, M. W., Scholz, C.
Format: Artigo
Jezik:Inglês
Izdano: Georg Thieme Verlag KG 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4873296/
https://ncbi.nlm.nih.gov/pubmed/27239063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0042-106209
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items